GlassScriptPhysician profile
Baylea Willis
NPI 1366151359
$1,854.19
in general payments reported to CMS, 2019-2025
26 companies · $881 in 2025
The $881 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $542 · 2024: $432 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840 · Education: $14.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.60 |
| Education | $14.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $287.28 | 2023-2025 | Entyvio, Gattex |
| Lilly USA, LLC | $263.30 | 2024-2025 | Omvoh, Zepbound, Mounjaro |
| Janssen Biotech, INC. | $238.37 | 2023-2025 | Tremfya, Stelara |
| Pacira Pharmaceuticals Incorporated | $142.15 | 2023-2025 | Exparel |
| Alcresta Therapeutics, INC. | $94.40 | 2023-2025 | Relizorb |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.36 | 2023 | Cyltezo |
| Becton, Dickinson and Company | $79.84 | 2023-2024 | Phasix Mesh |
| Daiichi Sankyo INC. | $74.66 | 2023-2025 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $62.93 | 2023 | Seglentis |
| Davol INC. | $60.08 | 2025 | Phasix Mesh, Channel Drain |
| Biocon Biologics INC | $48.64 | 2025 | Yesintek |
| Vertex Pharmaceuticals Incorporated | $46.40 | 2025 | |
| Dilon Technologies, INC. | $38.90 | 2025 | Hemoblast Bellows |
| Madrigal Pharmaceuticals | $38.61 | 2025 | Rezdiffra |
| Novo Nordisk INC | $37.01 | 2023-2025 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $32.38 | 2023-2024 | Hadlima |
| Celltrion USA INC. | $32.22 | 2023-2025 | Vegzelma, Yuflyma |
| Edwards Lifesciences Corporation | $29.29 | 2024 | |
| Baxter Healthcare | $24.16 | 2023 | Tisseel |
| Histosonics, INC. | $22.96 | 2025 | |
| La Jolla Pharmaceutical Company | $21.12 | 2024 | Xerava |
| Aimmune Therapeutics, INC. | $20.60 | 2025 | Zenpep |
| Enterra Medical, INC. | $19.49 | 2025 | |
| Myriad Genetic Laboratories, INC. | $18.42 | 2023 | Myrisk |
| Braintree Laboratories, INC. | $16.47 | 2024 | Sutab, Suflave |
| Hollister Incorporated | $16.15 | 2025 | Hollister |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baylea Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.